UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 2016
Reata Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
DELAWARE |
001-37785 |
11-3651945 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
2801 Gateway Dr, Suite 150 Irving, Texas |
|
75063 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (972) 865-2219
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07. Submission of Matters to a Vote of Security Holders.
On September 14, 2016, Reata Pharmaceuticals, Inc. (the “Company”) held its 2016 Annual Meeting of Stockholders (the “Annual Meeting”). As of August 5, 2016, the record date for the Annual Meeting (the "Record Date"), 14,585,273 shares of the Company’s Class A common stock (“Class A Common Stock”) and 7,740,354 shares of the Company’s Class B common stock (“Class B Common Stock”) were outstanding and entitled to vote at the Annual Meeting. Holders of Class A common stock were entitled to one vote per share held as of the Record Date, and holders of the Company's Class B common stock were entitled to three votes per share held as of the Record Date. A summary of the matters voted upon by the stockholders and the final voting results for each such matter are set forth below.
Proposal 1 – Election of Directors to the Board
Each of the following persons was duly elected by the Company’s stockholders as a director for the term expiring in 2019, with votes as follows:
|
Nominee |
Votes For |
Votes Withheld |
Broker Non-Vote |
|
J. Warren Huff |
44,928,071 |
567,214 |
1,154,739 |
|
Jack B. Nielsen |
44,811,667 |
683,618 |
1,154,739 |
Proposal 2 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm
The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2016, was ratified by the stockholders, with votes as follows:
|
Votes For |
Votes Against |
Votes Abstain |
Broker Non-Vote |
|
46,633,557 |
2,861 |
13,606 |
0 |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Reata Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
Dated: September 15, 2016 |
|
By: |
/s/ J. Warren Huff |
|
|
|
|
J. Warren Huff |
|
|
|
|
Chief Executive Officer |
3